ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト：[email protected]AIアクセス：llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
戻る
化工社化工社 化学情報印刷レポート · 研究参考用
HCID 237作成日：2026年11月5日

メパクリン

N-[4-(ジエチルアミノ)-1-メチルブチル]-2-メトキシ-6-クロロアクリジン-9-アミン · 6-クロロ-9-[[4-(ジエチルアミノ)-1-メチルブチル]アミノ]-2-メトキシアクリジン · N,N-ジエチル-N'-(2-メトキシ-6-クロロアクリジン-9-イル)ペンタン-1,4-ジアミン · キナクリン · N-(2-メトキシ-6-クロロ-9-アクリジニル)-N',N'-ジエチル-1-メチルテトラメチレンジアミン · アタブリン · アクリナミン · アンチマラリナ

https://huagongshe.com/ja/chemical/237

メパクリン の分子構造式

識別子と物理属性

CAS No.83-89-6
分子式C23H30ClN3O
平均分子量400 g/mol
単同位体質量399.2077403 g/mol
SMILESCCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12
InChIKeyGPKJTRJOBQGKQK-UHFFFAOYSA-N
PubChem CID237
ChEMBLCHEMBL2105615
ChEBICHEBI:8711
EC No.201-508-7
DTXSIDDTXSID7022627
現地名メパクリン

化学・物理的性質

XLogP6
極性表面積37.4
水素結合供与体数1
水素結合受容体数4
回転可能結合数9
重原子数28
形式電荷0
複雑度461
LogP（分配係数）5.5
Color/FormBright yellow crystals
溶解度Slight1g in 36 ml waterSlightly soluble in ethanolInsoluble in alcohol, benzene, chloroform and ether2.39e-03 g/LMethanol (Slightly), Water (Slightly)
融点248-250 °CDecomposes at 248 °CMelting point: ca 250 °C /Hydrochloride/248 - 250 °C247-250 °C
Physical DescriptionSolid
Stability/Shelf LifeSensitive to light. /Quinacrine hydrochloride/
Dissociation Constants10.3
Collision Cross Section194.62 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]192.67 Ų [M+K]+ [CCS Type: TW
Other Experimental PropertiesUpon decomposition emits NOxBright bright yellow crystals. Decomposes 248-258 °C. MP poorly discernable. 1 gram soluble in 35 mL water. Slightly soluble in Ethanol. Somewhat more soluble in methanol. Insoluble in ether, benzene and acetone. pH of 1% aq soln approx 4.5. Under UV light yellow aq soln exhibit a vivid fluorescence whihc is detectable in dilution of 1:5,000,000. /Dihydrochloride dihydrate/Bright bright yellow crystals1 part dissolves in 3 parts water at 15.5 °C, 36 parts ethanol at 15.5 °C. pH of 2% soln 3-5 /Methane sulfonate/Yellowish needles from watermax absorption (water, pH 6.5): 343 nm (log E= 3.7)424 nm (log E= 3.9)444 nm (log E= 3.9) /Hydrochloride, dl/
沸点557.1±50.0 °C(Predicted)
密度1.0989 (rough estimate)
屈折率1.5790 (estimate)
外観・状態Solid
pKa（酸解離定数）10.47±0.25(Predicted)
色明るい黄色の結晶
EPAの化学物質情報Quinacrine (83-89-6)

安全性と法規制

保管条件Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F) in a light-resistant container, unless otherwise specified by manufacturer. Store in a tight container.
処分方法SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
相互作用Convulsive seizures have occurred in patients receiving quinacrine and corticosteroids concomitantly. /Quinacrine hydrochloride/Concurrent use /of primaquine/ with quinacrine may inhibit the metabolism of primaquine or may displace if from tissue-binding sites, thereby increasing serum concentrations and potential toxicity of primaquine.Aldehyde dehydrogenase may be inhibited by quinacrine, resulting in acummulation of acetaldehyde after alcohol ingestion and possibly "disulfram-like" reaction...
HepatotoxicityMepacrine has been reported to cause elevations in serum enzymes, but the frequency of such changes is unknown, arising after 1 to 6 weeks with a mixed pattern of enzyme elevations and resolving within 1 to 2 months of stopping. Most patients are asymptomatic and liver enzyme elevations can resolve with, and sometimes without dose modification. Clinically apparent liver injury from mepacrine has also been reported, but the clinical features of the injury have not been well defined. Because mepacrine causes a yellowing of the skin, jaundice is not a reliable finding and most reports of liver injury from mepacrine have not included bilirubin elevations. Nevertheless, several instances of acute liver failure and death have been attributed to mepacrine therapy, although the reports usually predated the availability of tests for hepatitis A, B and C and often lacked histological documentation. Mepacrine has also been implicated in cases of aplastic anemia and in hypersensitivity reactions with exfoliative dermatitis, suggestive of Stevens Johnson syndrome, conditions that can be associated with liver injury that may be severe.Likelihood score: E* (unproven but suspected cause of clinically apparent liver injury).
生態毒性値LC50 Ictalurus punctatus (Channel catfish) 198 mg/L/24 hr (95% confidence limit: 169-232 mg/L)staticLC50 Ictalurus punctatus (Channel catfish) 70 mg/L/48 hr (95% confidence limit: 59.3-82.6 mg/L)LC50 Lepomis macrochirus (Bluegill) 120 mg/L/24 hr (95% confidence limit: 73-198 mg/L)

用途

解説

アクリナミン．メパクリン(mepacrine)，キナクリン(quinacrine)ともいう．6,9-ジクロロ-2-メトキシアクリジンと4-アミノ-1-ジエチルアミノペンタンをフェノール中で加熱すると得られる．黄色の液体．塩酸塩C23H30N3OCl·2HCl·2H2Oは黄色の苦味のある結晶性粉末．分解点約250 ℃．抗マラリア剤アテブリンとして市販されている．

使用

anthelmintic, antimalarial, intercalating agent

LC50 Lepomis macrochirus (Bluegill) 79 mg/L/48 hr (95% confidence limit: 54.1-115.3 mg/L)
For more Ecotoxicity Values (Complete) data for QUINACRINE (10 total), please visit the HSDB record page.
環境中動態TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 4.9X10+6(SRC), determined from a structure estimation method(2), indicates that quinacrine is expected to be immobile in soil(SRC). Estimated pKa values of 9.4 and 10.7 (amine groups)(3) indicate quinacrine will exist almost entirely in the cation form at pH values of 5 to 9 and therefore volatilization from moist soil surfaces is not expected to be an important fate process. Quinacrine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.8X10-10 mm Hg(SRC), determined from a fragment constant method(4). Biodegradation data were not available(SRC, 2005).AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 4.9X10+6(SRC), determined from a structure estimation method(2), indicates that quinacrine is expected to adsorb to suspended solids and sediment(SRC). Estimated pKa values of 9.4 and 10.7 (amine groups)(3) indicate quinacrine will exist almost entirely in the cation form at pH values of 5 to 9 and therefore volatilization from water surfaces is not expected to be an important fate process. Cations generally adsorb more strongly to organic carbon and clay than their neutral counterparts(4). According to a classification scheme(5), an estimated BCF of 5,400(SRC), from an estimated log Kow of 5.75(6) and a regression-derived equation(7), suggests the potential for bioconcentration in aquatic organisms is very high(SRC). Hydrolysis is not expected to be an important environmental fate process since this compound lacks functional groups that hydrolyze under environmental conditions(8). Biodegradation data were not available(SRC, 2005).ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), quinacrine, which has an estimated vapor pressure of 1.8X10-10 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase quinacrine may be removed from the air by wet and dry deposition(SRC). Quinacrine absorbs at wavelengths >290 nm(3) and therefore may be expected to be susceptible to direct photolysis by sunlight(SRC).
Soil Adsorption/MobilityUsing a structure estimation method based on molecular connectivity indices(1), the Koc of quinacrine can be estimated to be 4.9X10+6(SRC). According to a classification scheme(2), this estimated Koc value suggests that quinacrine is expected to be immobile in soil. The estimated pKa values for quinacrine are 9.4 and 10.7(3), indicating that this compound will primarily exist in the cation form in the environment and cations generally adsorb more strongly to organic carbon and clay than their neutral counterparts(4).
Human Toxicity Excerpts/HUMAN EXPOSURE STUDIES/ ... People exposed to quinacrine dust in its manufacture have complained of seeing blue haloes or multicolored rings about lights. This has been attributed to brown particles 5-10 um in diameter deposited in the corneal epithelium. Discontinuation of exposure to quinacrine resulted in return of the corneas to normal, and relief of the assoc symptoms in all cases./SIGNS AND SYMPTOMS/ Although some adults have survived single quinacrine hydrochloride doses up to 25 g, a dose of 6.8 g has been fatal when given intraduodenally.Symptoms of acute quinacrine toxicity include CNS excitation with restlessness, insomnia, psychic stimulation, and seizuresGI disorders such as nausea, vomiting, abdominal cramps and diarrheavascular collapse with hypotension, shock, cardiac arrhythmias or arrestand yellow skin pigmentation./SIGNS AND SYMPTOMS/ Reversible corneal edema or deposits, manifested by visual halos, focusing difficulty, and blurred vision, have been reported in patients receiving long-term quinacrine therapy for suppression of malaria. Retinopathy has been reported rarely in patients receiving high doses of quinacrine for prolonged periods in the treatment of certain chronic diseases, but not patients receiving the drug for cestodiasis or suppression or treatment of malaria./CASE REPORTS/ In two patients quinacrine is alleged to have caused optic neuritis, but this does not seem positively established. In one of these cases, a child having malaria, possibly pulmonary tuberculosis, and iridocyclitis in one eye, developed transient optic neuritis in the other eye after receiving several doses of quinacrine plus pamaquine. In the second case the patient was taking quinine as well as quinacrine for malaria. This patient had xanthopsia for 10 days before gradually becoming blind. Papilledema was the only abnormality observed in the fundus. In the course of a month after quinacrine was discontinued, vision recovered completely, although quinine was still being given.For more Human Toxicity Excerpts (Complete) data for QUINACRINE (6 total), please visit the HSDB record page.
Artificial Pollution SourcesQuinacrine's production and use as an anitmalarial(1) may result in its release to the environment through various waste streams(SRC).
Environmental BioconcentrationAn estimated BCF of 5400 was calculated for quinacrine(SRC), using an estimated log Kow of 5.75(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is very high(SRC), provided the compound is not metabolized by the organism(SRC).
Volatilization from Water/SoilEstimated pKa values of 9.4 and 10.7 (amine groups) indicate quinacrine will exist almost entirely in the cation form at pH values of 5 to 9 and therefore volatilization from moist soil and water surfaces is not expected to be an important fate process. Quinacrine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.8X10-10 mm Hg(SRC), determined from a fragment constant method(2).
Non-Human Toxicity Excerpts/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Experimental administration of 0.375-0.5 g of quinacrine to dogs for 5-15 days produced disturbances in histology of optic nerves... These doses were, however, lethal for most of the animals./LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ This study investigated whether the growth of transplanted mammary tumors is altered in rats by treatment with the antimalarial drugs chloroquine (CQ) and quinacrine (QN). Female inbred F344 rats were divided into three experimental groups. Animals were injected ip with either CQ, QN or normal saline for 5 days/week throughout the entire experimental period (25 days). After 7 days of drug treatment each rat received sc one 2 mm aliquot of R3230AC mammary adenocarcinoma in the mid-thoracic region. Eighteen days after implantation, all rats were sacrificed and tumors were excised, weighed and measured. The results indicate that weights and volumes of tumors as well as tumor to body weight ratios were significantly higher in CQ and QN treated animals than those in saline treated animals. The final body weights of rats treated with QN were significantly lower than those treated with saline. The prostaglandin E2 content of tumors was significantly reduced by CQ treatment. Erythrocyte glutathione reductase activity coefficient and reduced glutathione concentrations remained unaffected by both treatments. These results suggest that CQ and QN have significant stimulatory effects on the growth of mammary adenocarcinoma in rats./LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ 120 mg/kg of quinacrine were injected subcutaneously into rats on the 13th through the 19th gestational days. Fetal death was increased but no defective fetuses were found. The level of quinacrine in the fetal liver was only 9 ug as conpared to the maternal liver of 549 ug.
Populations at Special Risk... Quinacrine ... /is a/ oxidizing agent and can cause methemoglobinemia or hemolytic anemia (especially in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency).
Environmental Abiotic DegradationQuinacrine is not expected to undergo hydrolysis in the environment due to the lack of hydrolyzable functional groups(1). Quinacrine absorbs at wavelengths >290 nm(2) and therefore may be susceptible to direct photolysis by sunlight(SRC).
毒性mma-sat 500 mg/plate TXAPA9 52,237,80
危険文句（R）36/37/38-22
危険表示Xn
安全措置（S）37/39-26
有害物質データ83-89-6(Hazardous Substances Data)